Tokyo Tape
Sign in
← M3

Quarterly report · Q2

2413.TEDINET S100S6AW
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥115.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥58.4bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥112.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥55.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥34.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥16.6bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥36.3bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥17.6bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥37.3bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥17.5bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥38.1bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥23.4bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.0bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥24.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥25.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥11.6bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥26.0bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥12.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥461.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥377.7bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥115.8bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥345.2bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥291.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥331.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥284.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥135.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥100.2bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥26.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥25.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥28.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥18.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥15.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥14.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥34.472023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥16.192023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥35.442022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.582022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥34.452023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥16.182023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥35.422022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.572022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥754m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥754m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥125m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥42m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥21m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥6m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥674m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥6.9bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥215m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥101m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥1.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-09-30¥45.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-07-01 → 2023-09-30¥23.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-09-30¥44.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-07-01 → 2023-09-30¥22.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥622m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-09-30¥18.4bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-07-01 → 2023-09-30¥9.5bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-09-30¥32.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-07-01 → 2023-09-30¥16.9bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-09-30¥32.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-07-01 → 2023-09-30¥16.9bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥11m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥0
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-09-30¥7.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-07-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥4m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥945m
—segment totalrevenue2023-04-01 → 2023-09-30¥116.4bn
—segment totalrevenue2023-07-01 → 2023-09-30¥58.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥114.6bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥57.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.7bn
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥733m
—segment totalsegment profit2023-04-01 → 2023-09-30¥34.4bn
—segment totalsegment profit2023-07-01 → 2023-09-30¥16.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥701m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥231m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥8.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥445m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥179m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.5bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥634m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥14.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.7bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥347m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥185m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-07-01 → 2022-09-30¥22.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-09-30¥40.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥664m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥2m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥18.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥304m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥865m
—segment totalrevenue2022-04-01 → 2022-09-30¥113.9bn
—segment totalrevenue2022-07-01 → 2022-09-30¥55.9bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥111.2bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥54.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.7bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥1.0bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥36.9bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥17.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 811
ItemContextValueUnit
Other comprehensive income IFRSPrior1YTDDuration13399000000JPY
Other comprehensive income IFRSCurrentYTDDuration12567000000JPY
Comprehensive income IFRSPrior1YTDDuration39364000000JPY
Comprehensive income IFRSCurrentYTDDuration37702000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration37246000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration35721000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration2118000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration1982000000JPY
Comprehensive income IFRSPrior1YTDDuration39364000000JPY
Comprehensive income IFRSCurrentYTDDuration37702000000JPY
Profit loss IFRSPrior1QuarterDuration12478000000JPY
Profit loss IFRSCurrentQuarterDuration11582000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-1000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration150000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-1000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration150000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration1530000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration1432000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration2098000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration1490000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration3627000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentQuarterDuration2922000000JPY
Other comprehensive income IFRSPrior1QuarterDuration3626000000JPY
Other comprehensive income IFRSCurrentQuarterDuration3072000000JPY
Comprehensive income IFRSPrior1QuarterDuration16104000000JPY
Comprehensive income IFRSCurrentQuarterDuration14654000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1QuarterDuration15554000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentQuarterDuration14045000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1QuarterDuration550000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentQuarterDuration609000000JPY
Comprehensive income IFRSPrior1QuarterDuration16104000000JPY
Comprehensive income IFRSCurrentQuarterDuration14654000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember29129000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember29704000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-36000000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember6131000000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember192912000000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember257840000000JPY
Equity IFRSPrior2YearInstant_NonControllingInterestsIFRSMember6113000000JPY
Equity IFRSPrior2YearInstant263954000000JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember24060000000JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember24060000000JPY
Profit loss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember1906000000JPY
Profit loss IFRSPrior1YTDDuration25966000000JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember13186000000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember13186000000JPY
Other comprehensive income IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember213000000JPY
Other comprehensive income IFRSPrior1YTDDuration13399000000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass